Theravance Biopharma (NASDAQ:TBPH) Stock Price Passes Below 200-Day Moving Average – What’s Next?

Theravance Biopharma, Inc. (NASDAQ:TBPH) shares passed below its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $8.77 and traded as low as $8.56. Theravance Biopharma shares last traded at $8.80, with a volume of 102,008 shares traded.

Analysts Set New Price Targets

A number of research analysts recently commented on TBPH shares. Leerink Partners cut Theravance Biopharma from an “outperform” rating to a “market perform” rating and decreased their price target for the stock from $15.00 to $10.00 in a research report on Tuesday, August 6th. TD Cowen decreased their target price on shares of Theravance Biopharma from $10.00 to $9.00 and set a “hold” rating on the stock in a report on Tuesday, August 6th. Leerink Partnrs downgraded shares of Theravance Biopharma from a “strong-buy” rating to a “hold” rating in a report on Tuesday, August 6th. HC Wainwright reissued a “buy” rating and issued a $15.00 price objective on shares of Theravance Biopharma in a research note on Monday, September 16th. Finally, StockNews.com cut Theravance Biopharma from a “buy” rating to a “hold” rating in a research note on Saturday, August 10th. Four analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. Based on data from MarketBeat, Theravance Biopharma currently has a consensus rating of “Hold” and an average price target of $13.75.

Theravance Biopharma Stock Performance

The company’s 50 day moving average is $8.18 and its 200 day moving average is $8.77. The firm has a market cap of $427.97 million, a P/E ratio of -10.23 and a beta of 0.25.

Theravance Biopharma (NASDAQ:TBPH) last announced its quarterly earnings results on Monday, August 5th. The biopharmaceutical company reported ($0.34) EPS for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.25). The firm had revenue of $14.26 million during the quarter, compared to the consensus estimate of $15.81 million. Theravance Biopharma had a negative net margin of 73.61% and a negative return on equity of 21.29%. During the same quarter in the previous year, the company posted ($0.28) earnings per share. On average, equities research analysts anticipate that Theravance Biopharma, Inc. will post -1.04 EPS for the current year.

Insider Activity

In other news, major shareholder Eli Samaha acquired 999,800 shares of the stock in a transaction dated Wednesday, August 7th. The stock was bought at an average price of $7.80 per share, with a total value of $7,798,440.00. Following the completion of the purchase, the insider now directly owns 9,511,150 shares of the company’s stock, valued at $74,186,970. This represents a 0.00 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 6.90% of the company’s stock.

Institutional Trading of Theravance Biopharma

Institutional investors have recently modified their holdings of the business. Hsbc Holdings PLC bought a new position in Theravance Biopharma during the 2nd quarter worth $108,000. XTX Topco Ltd bought a new position in shares of Theravance Biopharma during the second quarter worth about $129,000. State Board of Administration of Florida Retirement System lifted its stake in shares of Theravance Biopharma by 28.2% in the first quarter. State Board of Administration of Florida Retirement System now owns 22,671 shares of the biopharmaceutical company’s stock worth $203,000 after acquiring an additional 4,990 shares during the period. Los Angeles Capital Management LLC bought a new stake in Theravance Biopharma in the second quarter valued at approximately $286,000. Finally, BNP Paribas Financial Markets increased its position in Theravance Biopharma by 30.7% during the 1st quarter. BNP Paribas Financial Markets now owns 33,458 shares of the biopharmaceutical company’s stock valued at $300,000 after purchasing an additional 7,851 shares during the period. Institutional investors own 99.10% of the company’s stock.

About Theravance Biopharma

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.